Login to Your Account

Street coolish on AC effort as Aldeyra readies for FDA talks on design of phase III

By Randy Osborne
Staff Writer

Wednesday, June 14, 2017

Aldeyra Therapeutics Inc. CEO Todd Brady told BioWorld that the missed phase IIb primary endpoint with aldehyde trapper ADX-102 in allergic conjunctivitis (AC) was “retrofitted for another class of drugs [i.e., antihistamines], which is inactive after five to 10 minutes.”

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription